File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy

TitleRegulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy
Authors
Issue Date1986
PublisherAmerican Society for Clinical Investigation. The Journal's web site is located at http://www.jci.org
Citation
Journal Of Clinical Investigation, 1986, v. 77 n. 5, p. 1632-1638 How to Cite?
AbstractInterferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. The binding characteristics of IFN to human lymphocytes were studied using IFN α2 labeled with 125I to high specific activity. The specific binding curves generated were analyzed by the LIGAND program of Munson and Rodbard to determine receptor numbers. The number of receptors in peripheral blood lymphocytes (PBL) and tonsillar B-lymphocytes (TBL) from normal individuals were 505 ± 293 (n = 10) and 393 ± 147 (n = 3) respectively. When these cells were preincubated in vitro with unlabeled IFN α2, the receptor number decreased to 82 ± 45 and 61 ± 16 respectively. Receptor binding activities recovered gradually over a period of 72 h when the cells were incubated in IFN-free medium. This recovery of receptors could be blocked by the addition of actinomycin D to the incubation medium. A similar decrease in receptor expression was observed in vivo in PBL from patients being treated daily with 5 x 106 units/m2 per d of IFN α2 by subcutaneous injection, for acute lymphoblastic leukemia or papilloma virus infections. Receptor numbers in PBL in vivo were further reduced concurrent with the progression of IFN therapy. Thus the reduction in IFN receptor expression observed in vitro can be demonstrated in vivo. These studies indicate that monitoring IFN receptor expression in vivo can provide information regarding the availability of IFN receptors at the cell surface for the mediation of IFN actions during the course of IFN therapy.
Persistent Identifierhttp://hdl.handle.net/10722/170214
ISSN
2015 Impact Factor: 12.575
2015 SCImago Journal Rankings: 8.764
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, ASen_US
dc.contributor.authorHannigan, GEen_US
dc.contributor.authorFreedman, MHen_US
dc.contributor.authorWilliams, BRGen_US
dc.date.accessioned2012-10-30T06:06:44Z-
dc.date.available2012-10-30T06:06:44Z-
dc.date.issued1986en_US
dc.identifier.citationJournal Of Clinical Investigation, 1986, v. 77 n. 5, p. 1632-1638en_US
dc.identifier.issn0021-9738en_US
dc.identifier.urihttp://hdl.handle.net/10722/170214-
dc.description.abstractInterferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. The binding characteristics of IFN to human lymphocytes were studied using IFN α2 labeled with 125I to high specific activity. The specific binding curves generated were analyzed by the LIGAND program of Munson and Rodbard to determine receptor numbers. The number of receptors in peripheral blood lymphocytes (PBL) and tonsillar B-lymphocytes (TBL) from normal individuals were 505 ± 293 (n = 10) and 393 ± 147 (n = 3) respectively. When these cells were preincubated in vitro with unlabeled IFN α2, the receptor number decreased to 82 ± 45 and 61 ± 16 respectively. Receptor binding activities recovered gradually over a period of 72 h when the cells were incubated in IFN-free medium. This recovery of receptors could be blocked by the addition of actinomycin D to the incubation medium. A similar decrease in receptor expression was observed in vivo in PBL from patients being treated daily with 5 x 106 units/m2 per d of IFN α2 by subcutaneous injection, for acute lymphoblastic leukemia or papilloma virus infections. Receptor numbers in PBL in vivo were further reduced concurrent with the progression of IFN therapy. Thus the reduction in IFN receptor expression observed in vitro can be demonstrated in vivo. These studies indicate that monitoring IFN receptor expression in vivo can provide information regarding the availability of IFN receptors at the cell surface for the mediation of IFN actions during the course of IFN therapy.en_US
dc.languageengen_US
dc.publisherAmerican Society for Clinical Investigation. The Journal's web site is located at http://www.jci.orgen_US
dc.relation.ispartofJournal of Clinical Investigationen_US
dc.subject.meshDactinomycin - Pharmacologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon Type I - Metabolism - Therapeutic Useen_US
dc.subject.meshIodine Radioisotopes - Diagnostic Useen_US
dc.subject.meshLeukemia, Lymphoid - Therapyen_US
dc.subject.meshLymphocytes - Analysis - Drug Effectsen_US
dc.subject.meshPapillomaviridaeen_US
dc.subject.meshReceptors, Immunologic - Analysis - Drug Effectsen_US
dc.subject.meshReceptors, Interferonen_US
dc.subject.meshTumor Virus Infections - Therapyen_US
dc.titleRegulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapyen_US
dc.typeArticleen_US
dc.identifier.emailLau, AS:asylau@hku.hken_US
dc.identifier.authorityLau, AS=rp00474en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1172/JCI112480-
dc.identifier.pmid3009549-
dc.identifier.scopuseid_2-s2.0-0022540517en_US
dc.identifier.volume77en_US
dc.identifier.issue5en_US
dc.identifier.spage1632en_US
dc.identifier.epage1638en_US
dc.identifier.isiWOS:A1986C111100030-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLau, AS=7202626202en_US
dc.identifier.scopusauthoridHannigan, GE=7004365563en_US
dc.identifier.scopusauthoridFreedman, MH=7203068454en_US
dc.identifier.scopusauthoridWilliams, BRG=7404502964en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats